Full bibliography
A clinical review of mpox for the Aotearoa New Zealand clinician
Resource type
Authors/contributors
- Donaldson, Annabelle (Author)
- Mathew, Teena (Author)
- Duffy, Eamon (Author)
- Smit, Erasmus (Author)
- Harrower, Jay (Author)
- Oliphant, Jeannie (Author)
- Bunkley, Noah (Author)
- Ingram, Joan (Author)
- Handy, Rupert (Author)
Title
A clinical review of mpox for the Aotearoa New Zealand clinician
Abstract
The World Health Organization declared mpox (formerly monkeypox) a Public Health Emergency of International Concern in July 2022. Aotearoa New Zealand has reported cases of mpox since July, with reports of locally acquired cases since October 2022. The 2022 global mpox outbreak highlights many features of the illness not previously described, including at-risk populations, mode of transmission, atypical clinical features, and complications. It is important that all clinicians are familiar with the variety of clinical manifestations, as patients may present to different healthcare providers, and taking lessons from the HIV pandemic, that all patients are managed without stigma or discrimination. There have been numerous publications since the outbreak began. Our narrative clinical review attempts to bring together the current clinical evidence for the New Zealand clinician.
Publication
New Zealand Medical Journal
Date
2023-02-17
Volume
136
Issue
1570
Pages
61-68
Journal Abbr
NZMJ
Accessed
7/6/25, 10:57 PM
ISSN
11758716
Language
en
Library Catalog
DOI.org (Crossref)
Notes
Study topic:
Clinical review of mpox (formerly monkeypox) for New Zealand clinicians, including epidemiology, clinical features, diagnosis, management, and public health guidance.
Study type:
Narrative clinical review.
Key findings:
- Mpox (formerly known as monkeypox) was declared a Public Health Emergency of International Concern in 2022 due to global outbreaks, including in Aotearoa New Zealand.
- Diagnosis in New Zealand requires a high index of suspicion, particularly in men who have sex with men presenting with mucocutaneous lesions and systemic symptoms.
- The paper emphasises the importance of timely notification to public health units and infection prevention strategies in general practice settings.
- HealthPathways is highlighted as a key platform for disseminating evolving clinical and public health advice about mpox to New Zealand clinicians.
- Equity concerns are noted, particularly regarding access to testing and care for Māori and Pasifika populations, underscoring the need for culturally safe communication pathways.
Citation
Donaldson, A., Mathew, T., Duffy, E., Smit, E., Harrower, J., Oliphant, J., Bunkley, N., Ingram, J., & Handy, R. (2023). A clinical review of mpox for the Aotearoa New Zealand clinician. New Zealand Medical Journal, 136(1570), 61–68. https://doi.org/10.26635/6965.6064
Link to this record